Vol 51, No 3 (2017)

open access

Page views 273
Article views/downloads 560
Get Citation

Connect on Social Media

Connect on Social Media

Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report

Vitalie Văcăraş1, Zoltán Zsigmond Major2, Anca Dana Buzoianu2
DOI: 10.1016/j.pjnns.2017.03.002
Neurol Neurochir Pol 2017;51(3):221-226.


Aim of the study

Our main purpose was to investigate if the chronic treatment with the disease-modifying drug natalizumab shows quantifiable effect on BDNF levels in multiple sclerosis patients.

Materials and Methods

BDNF plasma concentration was evaluated using enzyme-linked immunosorbent assay in healthy individuals, not treated multiple sclerosis patients and patients treated with natalizumab.


Multiple sclerosis patients have a significantly lower amount of peripheral BDNF than healthy individuals. Patients treated with natalizumab have significantly higher BDNF levels than not treated patients.


Chronic natalizumab treatment is associated with significantly increased plasma BDNF concentration in multiple sclerosis.

Article available in PDF format

View PDF Download PDF file

Neurologia i Neurochirurgia Polska